Table 3.
The pooling results of the therapy and prognosis of CMVR in aIDS patients.
Category | No. of studies | Pooled incidence | 95% CI | P-value | I 2 | Sensitivity analysis | Selected model | |
---|---|---|---|---|---|---|---|---|
Anti-HIV therapy during the entire courses | ||||||||
cART | 72 | 85% | 76% | 93% | P<0.01 | 98% | Negative | Random-effect model |
ART, no cART | 31 | 6% | 1% | 14% | P<0.01 | 95% | Negative | Random-effect model |
No ART | 51 | 9% | 4% | 15% | P<0.01 | 95% | Negative | Random-effect model |
Anti-CMV therapy | ||||||||
Systemic | 118 | 45% | 42% | 48% | P<0.01 | 98% | Negative | Random-effect model |
Local | 69 | 35% | 29% | 40% | P<0.01 | 99% | Negative | Random-effect model |
Combinational | 20 | 20% | 11% | 29% | P<0.01 | 99% | Negative | Random-effect model |
Prognosis | ||||||||
CMVR remission | ||||||||
Intraocular ganciclovir implant | 2 | 89% | 42% | 100% | P<0.01 | 96% | Negative | Random-effect model |
Intravitreal ganciclovir | 4 | 83% | 57% | 99% | P<0.01 | 78% | Negative | Random-effect model |
Intravenous ganciclovir | 11 | 90% | 79% | 98% | P<0.01 | 88% | Negative | Random-effect model |
Intravenous and intravitreal ganciclovir | 3 | 72% | 39% | 97% | P=0.04 | 68% | Negative | Random-effect model |
Intravitreal foscarnet | 3 | 72% | 28% | 100% | P<0.01 | 88% | Negative | Random-effect model |
Intravenous foscarnet | 3 | 92% | 83% | 98% | P=0.75 | 0% | Negative | Fixed-effect model |
CMVR progression | ||||||||
Intraocular ganciclovir implant | 6 | 17% | 11% | 24% | P=0.02 | 64% | Negative | Random-effect model |
Intravitreal ganciclovir | 5 | 37% | 3% | 81% | P<0.01 | 97% | Negative | Random-effect model |
Intravenous ganciclovir | 15 | 37% | 24% | 52% | P<0.01 | 92% | Negative | Random-effect model |
Oral ganciclovir | 4 | 56% | 23% | 86% | P<0.01 | 98% | Negative | Random-effect model |
Intravenous foscarnet | 3 | 7% | 2% | 13% | P=0.87 | 0% | Negative | Fixed-effect model |
Intravitreal cidofovir | 2 | 9% | 4% | 16% | P=0.21 | 36% | Negative | Fixed-effect model |
Intravenous cidofovir | 2 | 52% | 41% | 63% | P=0.16 | 48% | Negative | Fixed-effect model |
CMVR recurrence after discontinuing maintenance anti-CMV therapy | 7 | 16% | 4% | 31% | P<0.01 | 78% | Negative | Random-effect model |
All-cause mortality | 46 | 36% | 28% | 44% | P<0.01 | 96% | Negative | Random-effect model |
Incidence of IRU a | 28 | 26% | 19% | 34% | P<0.01 | 95% | Negative | Random-effect model |
IRU represents an increase in or new-onset of intraocular inflammation in the anterior chamber or vitreous of an eye with CMVR coincident with immune recovery after initiating cART.
AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; cART, combination antiretroviral therapy; CI, confidence interval; CMV, cytomegalovirus; CMVR, cytomegalovirus retinitis; IRU, immune recovery uveitis.